Sort   by:  
 Page size 
ProteomicsOptimized Method for Cell Surface Protein Identification on Primary B-Cell Precursor Acute Lymphoblastic Leukemia Cells
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is caused by abnormal expansion of immature B cells. Genetic alterations can be identified in most of the BCP-ALL cases, however, some specific lesions including rearrangements of the mixed lineage leukemia (MLL) gene encoding lysine methyltran...
ORGANISM(S): Homo sapiens (Human) 
2025-06-09 | PXD058992 | Pride
Leukemia Patient-derived xenograft Mixed lineage leukemia Target B cell Immunotherapy Pdx Biotinylation Bcp-all Surfaceome 
ProteomicsONGOING CHROMOSOMAL INSTABILITY ACROSS ANEUPLOID SUBTYPES OF CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ASSOCIATES WITH DISEASE PROGRESSION
Chromosomal instability (CIN), defined as an increased occurrence of chromosome segregation errors during cell division, is a prominent form of genomic instability (Bakhoum and Avi Landau, 2017). It is the major cause of aneuploidy, an imbalanced complement of whole chromosomes or chromosome arms, w...
ORGANISM(S): Homo sapiens (Human) 
2023-09-15 | PXD042785 | Pride
Aneuploidy B-cell acute lymphoblastic leukemia Childhood b-all Chromosomal instability 
ProteomicsPreclinical study with a CD40 agonist on patient-derived xenograft mice for the treatment of B-cell acute lymphoblastic leukemia
To induce leukemia in NOD/SCID/γc−/− (NSG) mice, we injected 10^5 human B-ALL cells, into the tail vein of non-irradiated mice. Two different PDX mice models were studied (PDX-1; #1 and PDX-2; #2). The InVivoMAb anti-human CD40 antibody (BE0189, clone G28.5, BioXCell) was i.v. administrated (CD40) a...
ORGANISM(S): Homo sapiens (Human) 
2024-10-10 | PXD047749 | Pride
Preclinical study Pdx models Agonist cd40 B-all leukemia Proteomic data 
GenomicsInducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL
Inducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL
PRJNA642171 | ENA
ProteomicsProteomic analysis of patient-derived xenograft samples from children with B-cell acute lymphoblastic leukemia harboring TCF3::PBX1 and TCF3::HLF translocations
Despite improved 5-year overall survival rates in B-cell acute lymphoblastic leukemia (B-ALL) due to therapy escalation, effective treatments for relapsed and treatment-resistant disease, especially in specific subtypes like those with TCF3 (formerly E2A) fusions, remain scarce. TCF3, a key regulato...
ORGANISM(S): Homo sapiens (Human) 
2024-07-05 | PXD053677 | Pride
Patient-derived xenograft B-cell acute lymphoblastic leukemia Tcf3::pbx1 Tcf3::hlf 
GenomicsVincristine induces spermatogenic impairment in a B-ALL PDX mouse model via downregulation of Tssk4 and Ccdc159: RNA-seq transcriptomic profiling
Vincristine induces spermatogenic impairment in a B-ALL PDX mouse model via downregulation of Tssk4 and Ccdc159: RNA-seq transcriptomic profiling
PRJNA1392611 | ENA
TranscriptomicsInducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL
Clinically relevant methods are not available that prioritize and validate potential therapeutic targets for individual tumors from the vast amount of tumor descriptive expression data. We established inducible transgene expression in clinically relevant patient-derived xenograft (PDX) models in viv...
ORGANISM(S): Homo sapiens 
2020-06-27 | GSE153382 | GEO
GenomicsmiR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease [BulkRNA 1]
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease [BulkRNA 1]
PRJNA989122 | ENA
UnknownInducible transgene expression in PDX models in vivo identifies KLF4 as a therapeutic target for B-ALL.
Not available
S-EPMC7493381 | biostudies-literature
GenomicsmiR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease [RNASeq 2]
miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease [RNASeq 2]
PRJNA989129 | ENA
Sort   by:  
 Page size